Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304 - Wikidata - awgldk - TriplyDB

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

http://www.wikidata.org/entity/Q24621743

about

Perampanel add-on for drug-resistant partial epilepsy Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review Perampanel Perampanel for focal epilepsy: insights from early clinical experience Antiepileptic Drug Treatment in Children with Epilepsy Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability Recent treatment advances and novel therapeutic approaches in epilepsy Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures The enigma of placebo effects in drug-refractory epilepsies Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist AMPA receptors as a molecular target in epilepsy therapy Review of clinical studies of perampanel in adolescent patients Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures Efficacy of perampanel: a review of clinical trial data.Safety and tolerability of perampanel: a review of clinical trial data.Efficacy of perampanel: a review of pooled data.Adverse effects and safety profile of perampanel: a review of pooled data.Confusing placebo effect with natural history in epilepsy: A big data approach Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study.Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children.Practice Update: Review of Anticonvulsant Therapy.Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.[New aspects in the field of epilepsy].Perampanel: What is its Place in the Management of Partial Onset Epilepsy?The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience.Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy.Time to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpoint Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Response to placebo in clinical epilepsy trials--Old ideas and new insights Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.AMPA Receptor Antagonist NBQX Decreased Seizures by Normalization of Perineuronal Nets Evaluate the Efficacy and Safety of Anti-Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta-Analysis.Screening for AMPA receptor auxiliary subunit specific modulators.A big data approach to the development of mixed-effects models for seizure count data.Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel.New drug classes for the treatment of partial onset epilepsy: focus on perampanel.Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials.

P2860

Q24200843-177D313C-397A-4A46-B135-98A12C13675C Q26743786-C308E9F4-BC11-44E4-8455-0BDFCD58E3AC Q26773308-6EAFF896-1DDD-4770-9D43-6D3CA61BED76 Q26778392-6DBEE70D-7943-474A-A8E7-5EA1A403BF54 Q26781771-7084464E-758E-4192-A4DE-59C6E2F48F7B Q26796447-FFA1A800-963C-4FD9-BF89-EDC7AFD95C81 Q26824512-9AAE8948-80E9-4DC9-BACD-9335C2C742C9 Q27007851-55CD8DE4-04BB-4FA0-9071-BB7D1057E01D Q27014928-864CD153-4B39-4AC1-970A-2AFDF9632F1A Q27022395-C8482B58-F6F2-4DB7-9DB1-C4012BB83D60 Q27026055-2666487E-0C72-4AE0-8179-847EC543D510 Q28077432-2401D8DA-DF6F-418B-A8D2-A8C1D63CD619 Q28078666-A77F86E0-D082-48BD-8109-9D47CF4740E4 Q30597531-7F7678D4-1BC6-4901-A75F-8F91E4EC7635 Q30597533-3CDD4BDE-DC6F-4CAC-90FC-7D6F769D6913 Q30728243-E8890AD3-E940-44A7-A71F-2947D4E14C08 Q30728256-0FE3204A-93A0-46B5-919D-1A14550A6548 Q30978984-5D1DFE1E-A311-4C7E-9BAC-AE410B19BB52 Q31140311-B3BF2CB8-95D7-4D5F-9F31-4218D2AAB016 Q33661884-73C21426-0AD6-4D35-8B9F-AD451881FD9C Q34086531-94FF4E22-092E-4DF5-B543-C83C965644EA Q34439257-08F170EE-812E-4FFE-81F3-1E1E01F95125 Q34518509-4A3F4EFB-7EF6-4DF7-97ED-4F79B84E8D36 Q34823061-35A6112F-39F8-487B-BA3E-8C86B4DB1BE9 Q35206626-4E1ACF90-5B10-4403-8F69-840A2B790E1B Q35309243-26C62E8B-4914-4AB0-B8C9-180338AE9517 Q35537344-6CB6C71D-C4E9-433B-A053-41D0E896021F Q35611628-76816F97-9FFB-48C8-B9C7-605724E95F99 Q35639962-8511C645-CC41-40B5-B81B-529BD49EAFCC Q35761335-DBCA949D-F767-4461-8E10-09822FE1FD73 Q35938221-4E4FB6A6-E5F8-474C-A7F6-354A07AA449D Q36052924-49DE5C68-15A5-463A-A57C-4B4CA7662411 Q36202511-D1FF2080-8511-4689-BF80-C3678464747D Q36284727-8B2DE381-4CE1-4A88-8496-726A87FFC45A Q36328451-4887AB68-5E8C-4D40-ABA8-667964C2FDA3 Q36332317-D398BC6D-9225-4F79-BF5C-A54938996576 Q36554228-00EFF234-0174-411B-972B-D2CEBF807B10 Q36592836-C81E0A41-93DE-476A-BF23-74EFBB54A0A7 Q37014640-EE52B29B-6AB4-4B6E-99AC-F81B28271D15 Q37149455-B99F5574-B344-4239-A228-44EC4BC30121

P2860

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

http://www.wikidata.org/entity/Q24621743

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Adjunctive perampanel for refr ...... randomized phase III study 304

@ast

Adjunctive perampanel for refr ...... randomized phase III study 304

@en

Adjunctive perampanel for refr ...... randomized phase III study 304

@nl

type

label

Adjunctive perampanel for refr ...... randomized phase III study 304

@ast

Adjunctive perampanel for refr ...... randomized phase III study 304

@en

Adjunctive perampanel for refr ...... randomized phase III study 304

@nl

prefLabel

Adjunctive perampanel for refr ...... randomized phase III study 304

@ast

Adjunctive perampanel for refr ...... randomized phase III study 304

@en

Adjunctive perampanel for refr ...... randomized phase III study 304

@nl

P1433

Q24621743-BAE07732-06B1-4D39-9EE3-23505088FF7A

P1476

Q24621743-7E4C8B9D-BAEA-4717-84FF-D4EBB19683B5

P2093

Q24621743-1AE3E8BE-E989-42A8-939A-195223AC759A

Q24621743-698EB210-6811-4566-8533-6AECEC3E0CA3

Q24621743-B175FEAC-D19A-4501-9555-B3EEEF59856F

Q24621743-C8B2C84F-576A-4B2F-8AEE-0733AFE52EA2

Q24621743-CC34D59B-4169-4D19-965D-FBCDCA83F60F

Q24621743-CFD59FA9-DEC7-42CB-A88D-A04A7404E7B2

P2860

Q24621743-07D08AE4-5555-4A3C-A7F7-B83B2912E251

Q24621743-1842E874-F2F9-45BA-922D-54EA59336131

Q24621743-3B5FEC3B-29F0-45CC-B201-3254B47B84F4

Q24621743-893B7AA8-A5B2-458D-8661-D5D2B04D2FD8

Q24621743-8A6CBD20-CFFC-4894-98C5-2AC24C7637A2

Q24621743-95B48304-565F-4CAC-85A8-7607E9E616BC

Q24621743-E8382978-119D-400C-9787-12CBCB4568CF

P304

Q24621743-20EA8793-B04C-4DD3-AFE5-5616F623954F

P31

Q24621743-89AE6BF1-CCD1-4715-9CF2-19F357184C93

P3181

Q24621743-FC9C1FC0-4CC8-4C7F-A873-3795F948F00E

P356

Q24621743-0E14B554-5045-43FB-A926-26444398633B

P407

Q24621743-754E7F54-7D13-44C0-AB4A-FC2CE2D3A361

P433

Q24621743-9BE99EDE-0D84-4485-B652-AB27C6F5B93E

P478

Q24621743-BF1FF343-B4B1-49E2-9F3A-6140A47490B8

P50

Q24621743-142AFF7D-6393-4DAA-AA7E-223867A1EECE

Q24621743-AC7885AD-9220-40D7-8B72-F080A0FD207A

P577

Q24621743-9AF761C0-04F2-4C1A-A8B6-19DC9748913D

P698

Q24621743-5F907F90-88B8-48CC-B1EE-AE32A22F5D4A

P921

Q24621743-8F21B7EB-1F9B-450E-8CEB-2F5A7A82BBEB

P932

Q24621743-6D875DA1-042C-4F87-885C-9FEFA65D33A6

P3181

P356

WNL.0B013E3182635735

P1433

P1476

Adjunctive perampanel for refr ...... randomized phase III study 304

@en

P2093

Antonio Laurenza

http://www.w3.org/2001/XMLSchema#string

David Squillacote

http://www.w3.org/2001/XMLSchema#string

Dinesh Kumar

http://www.w3.org/2001/XMLSchema#string

Gregory L Krauss

http://www.w3.org/2001/XMLSchema#string

Haichen Yang

http://www.w3.org/2001/XMLSchema#string

Victor Biton

http://www.w3.org/2001/XMLSchema#string

P2860

Revisiting AMPA receptors as an antiepileptic drug target

Molecular targets for antiepileptic drug development

Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy

Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs.

Tolerability and safety of perampanel: two randomized dose-escalation studies.

P304

589-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

312618

http://www.w3.org/2001/XMLSchema#string

P356

10.1212/WNL.0B013E3182635735

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline French

Michael A Rogawski

P577

2012-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22843280

http://www.w3.org/2001/XMLSchema#string

P921

P932

3413761

http://www.w3.org/2001/XMLSchema#string